DrugBiological
Magrolimab clinical trials
Also written Hu5F9-G4 and ONO-7913.
- studies test it
- 25
- open now
- 0
- in phase 3
- 3
- first study started
- 2014
How studies write it
Studies that test it under each name
Name
Other names
Studies by the year they started
25 studies that test it; most in 2021 (6)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 16
- Phase 2
- 10
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 9
Gilead Sciences (10) · National Cancer Institute (NCI) (3) · Hoffmann-La Roche (2) · M.D. Anderson Cancer Center (2) · Ono Pharmaceutical Co., Ltd. (1) · University of California, San Francisco (1) · Ono Pharmaceutical Co. Ltd (1) · Acerta Pharma BV (1)
Often tested with
Tested in the same studies.
Cisplatin (3) · Azacitidine (3) · Venetoclax (2) · Rituximab (2) · Gemcitabine (2) · Nivolumab (1) · Obinutuzumab (1) · Avelumab (1)
Studies
Open first, then newest update. How each study uses magrolimab is read from its arms, and is right about nine times in ten.
Testing it · 25
- An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic CancerActive, not recruitingPhase 1Ono Pharmaceutical Co., Ltd.NCT06532344Written as ONO-7913
- Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)TerminatedPhase 1/2Hoffmann-La RocheNCT03869190Written as Magrolimab (Hu5F9-G4)
- Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin LymphomaTerminatedPhase 2Ranjana AdvaniNCT04788043Written as Magrolimab
- Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid LeukemiaTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT04435691Written as Magrolimab
- Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell CarcinomaTerminatedPhase 2Gilead SciencesNCT04854499Written as Magrolimab
- Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to TreatmentTerminatedPhase 1/2National Cancer Institute (NCI)NCT04541017Written as Magrolimab
- Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain TumorsCompletedPhase 1University of California, San FranciscoNCT05169944Written as Magrolimab
- Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)TerminatedPhase 2Gilead SciencesNCT05330429Written as Magrolimab
- Study of Magrolimab in Patients With Solid TumorsTerminatedPhase 2Gilead SciencesNCT04827576Written as Magrolimab
- Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid LeukemiaTerminatedPhase 3Gilead SciencesNCT05079230Written as Magrolimab
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been TreatedTerminatedPhase 3Gilead SciencesNCT04778397Written as Magrolimab
- Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesCompletedPhase 1National Cancer Institute (NCI)NCT04599634Written as Magrolimab
- A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)TerminatedPhase 2Astex Pharmaceuticals, Inc.NCT05835011Written as Magrolimab
- Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDSWithdrawnPhase 1City of Hope Medical CenterNCT05823480Written as Magrolimab
- Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial CarcinomaWithdrawnPhase 1Insel Gruppe AG, University Hospital BernNCT05738161Written as Magrolimab
- Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)TerminatedPhase 3Gilead SciencesNCT04313881Written as Magrolimab
- ONO-7913 Phase I Study (ONO-7913)CompletedPhase 1Ono Pharmaceutical Co. LtdNCT04403308Written as ONO-7913
- Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA MutationsWithdrawnPhase 1National Cancer Institute (NCI)NCT05807126Written as Magrolimab
- Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum ChemotherapyCompletedPhase 1Gilead SciencesNCT03558139Written as Magrolimab
- An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell LymphomaWithdrawnPhase 2M.D. Anderson Cancer CenterNCT05929716Written as Magrolimab
See all 25 studies that test magrolimab →
Given in every arm · 10 — magrolimab is usual care beside what is tested
- The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal CancerActive, not recruitingPhase 1Ono Pharmaceutical Co., Ltd.NCT06540261Written as ONO-7913
- Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed OsteosarcomaTerminatedPhase 1National Cancer Institute (NCI)NCT04751383Written as Magrolimab
- Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast CancerTerminatedPhase 2Gilead SciencesNCT04958785Written as Magrolimab
- Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell CarcinomaTerminatedPhase 2M.D. Anderson Cancer CenterNCT06046482Written as Magrolimab
- Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's LymphomaTerminatedPhase 1/2Gilead SciencesNCT02953509Written as Magrolimab
- Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple MyelomaTerminatedPhase 2Gilead SciencesNCT04892446Written as Magrolimab
- Study of Magrolimab Combinations in Participants With Myeloid MalignanciesTerminatedPhase 2Gilead SciencesNCT04778410Written as Magrolimab
- Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological MalignanciesTerminatedPhase 1Gilead SciencesNCT03248479Written as Magrolimab
- A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS ParticipantsWithdrawnPhase 1/2Novartis PharmaceuticalsNCT05367401Written as Magrolimab
- Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDSWithdrawnPhase 2Uwe PlatzbeckerNCT05829434Written as Magrolimab
Codes
What other systems call magrolimab · ClinicalTrials.gg INT001017
- MeSH (NLM) C000629291magrolimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 90YIEHRFJ9MAGROLIMABConfirmed FDA, NLM
- NCI Thesaurus C117730MagrolimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629291 | magrolimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 90YIEHRFJ9 | MAGROLIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C117730 | Magrolimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.